Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.

T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.

AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis. 

Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.

Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.

AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.